The burgeoning popularity of tirzepatide , initially for metabolic conditions, is creating significant attention within the UK , prompting a notable shift in hormone trends. Obtaining these medications remains a complex landscape, with NHS coverage currently limited and specialist practices offering therapy at a substantial price. Concerns are bein